Bayer (BAYN) Hisse Özeti
Bayer Aktiengesellschaft dünya çapında bir yaşam bilimleri şirketi olarak faaliyet göstermektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 3/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden BAYN için herhangi bir risk tespit edilmedi.
BAYN Community Fair Values
Create NarrativeSee what 260 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
€40
FV
18.3% aşırı değerlenmiş içsel indirim174
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Bayer Aktiengesellschaft Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | €47.31 |
| 52 Haftanın En Yüksek Seviyesi | €53.92 |
| 52 Haftanın En Düşük Seviyesi | €24.81 |
| Beta | 0.83 |
| 1 Aylık Değişim | 25.03% |
| 3 Aylık Değişim | 18.36% |
| 1 Yıllık Değişim | 71.69% |
| 3 Yıllık Değişim | -8.12% |
| 5 Yıllık Değişim | -7.90% |
| Halka arzdan bu yana değişim | 247.37% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 08
BAYN: Litigation Ruling And Settlement Progress Will Drive Future Re Rating
The analyst price target for Bayer has been revised higher from €60.00 to €63.81 as analysts factor in recent upgrades tied to progress on glyphosate litigation and mixed, but generally more constructive, Street research. Analyst Commentary Recent Street research on Bayer has turned more constructive, with several bullish analysts highlighting progress on glyphosate litigation and updated views on the company's pharmaceutical outlook.Anlatı Güncellemesi • Jun 24
BAYN: Litigation Progress And Key Approvals Will Drive Future Re Rating
Analysts nudged their average price target for Bayer slightly higher to about €40.50, citing updated views on litigation risks, the outlook for the asundexian pipeline, and recent recalibrations of valuation multiples such as forward P/E. Analyst Commentary Recent Street research around Bayer highlights a mixed but gradually improving tone, with several bullish analysts adjusting price targets and ratings as they reassess litigation exposure, the asundexian opportunity, and the conglomerate discount.Recent updates
Anlatı Güncellemesi • Jul 08
BAYN: Litigation Ruling And Settlement Progress Will Drive Future Re Rating
The analyst price target for Bayer has been revised higher from €60.00 to €63.81 as analysts factor in recent upgrades tied to progress on glyphosate litigation and mixed, but generally more constructive, Street research. Analyst Commentary Recent Street research on Bayer has turned more constructive, with several bullish analysts highlighting progress on glyphosate litigation and updated views on the company's pharmaceutical outlook.Anlatı Güncellemesi • Jun 24
BAYN: Litigation Progress And Key Approvals Will Drive Future Re Rating
Analysts nudged their average price target for Bayer slightly higher to about €40.50, citing updated views on litigation risks, the outlook for the asundexian pipeline, and recent recalibrations of valuation multiples such as forward P/E. Analyst Commentary Recent Street research around Bayer highlights a mixed but gradually improving tone, with several bullish analysts adjusting price targets and ratings as they reassess litigation exposure, the asundexian opportunity, and the conglomerate discount.Analiz Makalesi • Jun 16
Bayer (XTRA:BAYN) Stock Could Be 9.2% Undervalued After FDA Approval Of AMBELVIST
Bayer (XTRA:BAYN) is back in focus after the U.S. FDA approved AMBELVIST, a macrocyclic gadolinium based contrast agent for contrast enhanced MRI in adults and pediatric patients, including term neonates. See our latest analysis for Bayer. Despite recent product and leadership announcements, Bayer’s 1 year total shareholder return of 32.05% contrasts with a 5 year total shareholder return that is down 24.26%, while its 90 day share price return is down 9.7%. This suggests longer term holders...Anlatı Güncellemesi • Jun 06
BAYN: Litigation Resolution And Key Drug Approvals Will Drive Future Re Rating
Narrative Update on Bayer Analysts have lifted Bayer's blended price target to €40, with many highlighting higher published targets from firms such as DZ Bank, Deutsche Bank, Jefferies and UBS. They are still pointing to litigation outcomes and the asundexian data readout as key swing factors.Anlatı Güncellemesi • May 22
BAYN: Easing Litigation Risks Will Support Re Rating And Future Upside Potential
Analysts have maintained the fair value estimate for Bayer at €60.00 and raised price targets in recent research, citing a series of upgrades, slightly higher assumptions for revenue growth and profit margins, as well as a modestly lower future P/E multiple following a broad reassessment of sector risks and company-specific legal developments. Analyst Commentary Recent research points to a clear shift toward more constructive views on Bayer, with several bullish analysts updating ratings and valuation frameworks in response to company specific developments and sector wide reassessments.
Anlatı Güncellemesi • May 05
BAYN: Future Litigation And Settlement Uncertainty Will Constrain Share Upside Potential
Analysts have nudged the fair value estimate for Bayer higher to about €31.26 from €30.41, citing a series of recent upgrades and higher price targets that reflect updated assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Bayer has been mixed, with several firms updating ratings and price targets over the past few months.Anlatı Güncellemesi • Apr 21
BAYN: Future Litigation Settlement Payouts Will Pressure Upside Potential
Analysts have lifted the Bayer fair value estimate from €23.00 to about €30.41, citing a series of recent price target increases and upgrades that reflect updated assumptions for revenue growth, profit margins, and P/E expectations. Analyst Commentary Recent research on Bayer shows a split in sentiment, with some firms becoming more constructive while others highlight ongoing risks to the investment case.Anlatı Güncellemesi • Apr 06
BAYN: Roundup Settlement Progress Will Reduce Litigation Overhang And Support Future Upside
Analysts maintain a fair value estimate for Bayer at €60.00. Recent adjustments to revenue growth, margin, and P/E assumptions come alongside mixed research actions, including several upgrades that point to potential resolution of litigation overhangs and margin upside, offset by at least one downgrade with a lower price target.Anlatı Güncellemesi • Mar 23
BAYN: Roundup Settlement Advances Will Support Future Upside In Core Earnings
Analysts have modestly adjusted Bayer's price targets to a range of €50 to €55, reflecting mixed views that balance recent upgrades tied to share price weakness, litigation progress and margin potential with at least one more cautious stance. Analyst Commentary Recent research points to a cluster of more optimistic views on Bayer, with several bullish analysts raising ratings or price targets as they reassess litigation risk, product potential and profitability in key segments.Anlatı Güncellemesi • Mar 09
BAYN: Roundup Settlement Progress Will Support Future Upside In Core Earnings
Analysts have revised their view on Bayer with a reduced implied P/E and updated margin expectations, while recent Street research shows a split between a Sell call at €42 and an Overweight stance at €45 that hinges on litigation resolution and potential upside in pharmaceuticals and Crop Science. Analyst Commentary Recent research on Bayer highlights a clear divide between cautious and optimistic views, with valuation closely linked to how investors think litigation, pharmaceutical assets and Crop Science margins will play out.Anlatı Güncellemesi • Feb 23
BAYN: Roundup Settlement Progress Will Unlock Future Equity Upside
The analyst fair value estimate for Bayer has been adjusted to €60 from €55. This reflects updated assumptions on revenue growth and future P/E, alongside mixed Street views, including a downgrade citing valuation risks and an upgrade pointing to potential progress on litigation and margins.Anlatı Güncellemesi • Feb 09
BAYN: Litigation Overhang Resolution Will Unlock Future Equity Upside
Analysts have nudged their Bayer price targets higher, with recent moves such as Barclays shifting to an Overweight rating with a €45 target and Berenberg raising its target to €30.40. They cite potential resolution of litigation issues, along with possible upside in Kerendia and Crop Science margins, as key supports for their updated views.Analiz Makalesi • Jan 27
The Market Lifts Bayer Aktiengesellschaft (ETR:BAYN) Shares 29% But It Can Do More
Despite an already strong run, Bayer Aktiengesellschaft ( ETR:BAYN ) shares have been powering on, with a gain of 29...Anlatı Güncellemesi • Jan 25
BAYN: Litigation Resolution And Crop Science Margins Will Unlock Future Upside
Analysts have raised their fair value estimate for Bayer from €47.98 to €55.00, citing the potential resolution of litigation issues, improved expectations for Kerendia, and margin opportunities in the Crop Science business as key supports for the higher target. Analyst Commentary Recent Street research points to a more constructive tone around Bayer, with several bullish analysts adjusting their views in ways that support the higher fair value estimate.
Anlatı Güncellemesi • Jan 09
BAYN: Litigation Overhang Will Drive Future Rerating Risk For Shares
Narrative Update Analysts have nudged their fair value estimate for Bayer from €33.42 to €34.97, citing updated assumptions for modestly higher revenue growth, slightly stronger profit margins, a higher future P/E, and growing confidence that litigation issues, Kerendia expectations, and Crop Science margins could be better than previously modeled. Analyst Commentary Recent Street research on Bayer has focused on how quickly the litigation overhang could be addressed, the role of Kerendia in the pharma portfolio, and the strength of margins in Crop Science.Anlatı Güncellemesi • Dec 26
BAYN Will Rely On Pipeline And Cost Cuts To Unlock Upside Potential
Analysts have raised their price target on Bayer to approximately EUR 48 from around EUR 37. They cite expectations for slightly faster revenue growth, improved profit margins, a modestly lower discount rate and a higher future earnings multiple that together support a higher fair value.Anlatı Güncellemesi • Dec 11
BAYN: Future Litigation Outcomes And Potential Ag Spin-Out Will Shape Shares
Analysts have nudged their Bayer price target higher to about EUR 30 from the mid‑20s, citing slightly faster expected revenue growth, modestly stronger profit margins, and a richer future P/E multiple. Together, these factors lift estimated fair value to roughly EUR 33 per share.Analiz Makalesi • Dec 03
Further Upside For Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Introduce Price Risks After 27% Bounce
Bayer Aktiengesellschaft ( ETR:BAYN ) shareholders have had their patience rewarded with a 27% share price jump in the...Anlatı Güncellemesi • Nov 27
BAYN: Future Litigation Decisions And Agriculture Spin-Out Will Guide Shares
Bayer's analyst price target increased from EUR 28.71 to EUR 29.57, as analysts cite improved forecasts for revenue growth and a recent uptick in target valuations across the sector. Analyst Commentary Bullish Takeaways Bullish analysts have raised Bayer's price targets in response to improved revenue forecasts.Analiz Makalesi • Nov 14
Bayer Aktiengesellschaft (ETR:BAYN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
It's been a pretty great week for Bayer Aktiengesellschaft ( ETR:BAYN ) shareholders, with its shares surging 13% to...Anlatı Güncellemesi • Nov 13
BAYN: Future Legal Outcomes And Sector Dynamics Will Determine Momentum
Analysts have raised Bayer's price target slightly from $28.53 to $28.71, reflecting steady profit margin improvements and updated industry positioning. This adjustment comes particularly in light of ongoing strategic shifts among major agribusiness peers.Hissedar Getirileri
| BAYN | DE Pharmaceuticals | DE Pazar | |
|---|---|---|---|
| 7D | -5.2% | -2.6% | -0.7% |
| 1Y | 71.7% | 41.1% | -0.9% |
Getiri vs. Endüstri: BAYN geçen yıl % 41.1 oranında getiri sağlayan German Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: BAYN geçen yıl % -0.9 oranında getiri sağlayan German Piyasasını aştı.
Fiyat Oynaklığı
| BAYN volatility | |
|---|---|
| BAYN Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.6% |
| 10% least volatile stocks in DE Market | 2.7% |
İstikrarlı Hisse Senedi Fiyatı: BAYN son 3 ayda German piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: BAYN 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1863 | 87,757 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft dünya çapında bir yaşam bilimleri şirketi olarak faaliyet göstermektedir. Şirket, İlaç, Tüketici Sağlığı ve Bitki Bilimi segmentleri aracılığıyla faaliyet göstermektedir. İlaç segmenti, öncelikle kardiyoloji ve kadın sağlığı hizmetleri için reçeteli ürünler; onkoloji, hematoloji ve oftalmoloji alanlarında özel terapötikler ve tanısal görüntüleme ekipmanı ve kontrast ajanlarının yanı sıra hücre ve gen tedavisi sağlar.
Bayer Aktiengesellschaft Temel Bilgiler Özeti
| BAYN temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | €47.61b |
| Kazançlar(TTM) | -€2.16b |
| Gelir(TTM) | €45.24b |
1.0x
P/S Oranı-21.6x
F/K OranıBAYN aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| BAYN gelir tablosu (TTM) | |
|---|---|
| Gelir | €45.24b |
| Gelir Maliyeti | €18.13b |
| Brüt Kâr | €27.11b |
| Diğer Giderler | €29.26b |
| Kazançlar | -€2.16b |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 04, 2026
| Hisse başına kazanç (EPS) | -2.19 |
| Brüt Marj | 59.92% |
| Net Kâr Marjı | -4.77% |
| Borç/Özkaynak Oranı | 134.3% |
BAYN uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
0.2%
Mevcut Temettü Verimi-5%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/20 18:47 |
| Gün Sonu Hisse Fiyatı | 2026/07/20 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Bayer Aktiengesellschaft 40 Bu analistlerden 17, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Rafael Bonardell Trianes | Banco de Sabadell. S.A. |
| Mark Purcell | Barclays |
| Charles Pitman | Barclays |